|
Name |
Palmarumycin CP(1)
|
Molecular Formula | C20H12O4 | |
IUPAC Name* |
8'-hydroxyspiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
|
|
SMILES |
C1=CC2=C3C(=C1)OC4(C=CC(=O)C5=C4C=CC=C5O)OC3=CC=C2
|
|
InChI |
InChI=1S/C20H12O4/c21-14-7-3-6-13-19(14)15(22)10-11-20(13)23-16-8-1-4-12-5-2-9-17(24-20)18(12)16/h1-11,21H
|
|
InChIKey |
LVOXAJYEGVDSQA-UHFFFAOYSA-N
|
|
Synonyms |
Palmarumycin CP(1); Palmarumycin CP1; 159933-90-1; CHEMBL88230; SCHEMBL17250054; DTXSID80166774; BDBM50218814; EN300-26619641; 5-hydroxy-4H-2',4'-dioxaspiro[naphthalene-1,3'-tricyclo[7.3.1.0,5,13]tridecane]-1'(13'),5',7',9',11'-pentaen-4-one; 8'-hydroxyspiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
|
|
CAS | 159933-90-1 | |
PubChem CID | 196959 | |
ChEMBL ID | CHEMBL88230 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 316.3 | ALogp: | 4.6 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 24 | QED Weighted: | 0.66 |
Caco-2 Permeability: | -4.914 | MDCK Permeability: | 0.00002100 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.751 |
Blood-Brain-Barrier Penetration (BBB): | 0.209 | Plasma Protein Binding (PPB): | 99.05% |
Volume Distribution (VD): | 0.541 | Fu: | 1.16% |
CYP1A2-inhibitor: | 0.96 | CYP1A2-substrate: | 0.121 |
CYP2C19-inhibitor: | 0.962 | CYP2C19-substrate: | 0.069 |
CYP2C9-inhibitor: | 0.931 | CYP2C9-substrate: | 0.933 |
CYP2D6-inhibitor: | 0.958 | CYP2D6-substrate: | 0.123 |
CYP3A4-inhibitor: | 0.863 | CYP3A4-substrate: | 0.243 |
Clearance (CL): | 2.385 | Half-life (T1/2): | 0.715 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.68 |
Drug-inuced Liver Injury (DILI): | 0.913 | AMES Toxicity: | 0.976 |
Rat Oral Acute Toxicity: | 0.866 | Maximum Recommended Daily Dose: | 0.736 |
Skin Sensitization: | 0.879 | Carcinogencity: | 0.961 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.939 |
Respiratory Toxicity: | 0.857 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001956 | 0.667 | D06TJJ | 0.365 | ||||
ENC003201 | 0.602 | D08CCE | 0.287 | ||||
ENC001112 | 0.573 | D0Q5UQ | 0.282 | ||||
ENC005582 | 0.573 | D02NTO | 0.279 | ||||
ENC005548 | 0.562 | D0B4DC | 0.266 | ||||
ENC003746 | 0.554 | D03YGR | 0.263 | ||||
ENC005583 | 0.554 | D0QV5T | 0.262 | ||||
ENC005524 | 0.554 | D00HPK | 0.262 | ||||
ENC002530 | 0.543 | D02TJS | 0.259 | ||||
ENC003199 | 0.543 | D0L6DA | 0.257 |